NASDAQ:ATYR aTyr Pharma Q3 2026 Earnings Results & Report $3.96 -0.13 (-3.06%) As of 02:43 PM Eastern This is a fair market value price provided by Massive. Learn more. aTyr Pharma missed analyst earnings expectations in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$7.43 versus the -$4.00 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 6, 2026TimeAfter Market ClosesConference Call DateNovember 5, 2026Conference Call4:00 PM ET aTyr Pharma EPS ResultsActual EPS-$7.43Consensus EPS -$4.00Beat/MissMissed by -$3.43One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersaTyr Pharma Revenue ResultsActual RevenueN/AExpected Revenue$2.50 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) aTyr Pharma Q3 2026 Earnings FAQ Did aTyr Pharma beat earnings estimates for Q3 2026? aTyr Pharma (NASDAQ:ATYR) reported earnings of -$7.43 per share for Q3 2026, missing the consensus estimate of -$4.00. The report was announced on Friday, November 6, 2026. aTyr Pharma Earnings HeadlinesATyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society 2026 Annual MeetingNovember 19 at 9:02 AM | marketscreener.comMaTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual MeetingNovember 19 at 7:00 AM | globenewswire.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 19 at 1:00 AM | Behind the Markets (Ad)aTyr Pharma (NASDAQ:ATYR) Stock Rating Lowered by Wall Street ZenNovember 14, 2026 | americanbankingnews.comaTyr Pharma (ATYR) Stock Fair Value Moves Lower As Phase III Funding Risks LoomNovember 13, 2026 | finance.yahoo.comFY2026 EPS Estimate for aTyr Pharma Reduced by AnalystNovember 12, 2026 | americanbankingnews.comSee More aTyr Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email. Email Address About aTyr PharmaaTyr Pharma (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on developing medicines based on the extracellular biology of tRNA synthetases, a family of proteins involved in cellular processes. The company is headquartered in San Diego, California. Its lead drug candidate, efzofitimod, is an immunomodulator being studied for pulmonary sarcoidosis and other interstitial lung diseases. The candidate is designed to act through neuropilin-2, a receptor involved in immune regulation. aTyr’s research programs draw on its work in tRNA synthetase biology, with the broader goal of developing treatments for inflammatory and fibrotic conditions. Its activities center on drug research and clinical development.View aTyr Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.